AGLE - Aeglea BioTherapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Aeglea BioTherapeutics, Inc.

805 Las Cimas Parkway
Suite 100
Austin, TX 78746
United States
512 942 2935

Full-time employees61

Key executives

NameTitlePayExercisedYear born
Mr. Jonathan D. Alspaugh M.B.A.Pres, CFO & Principal Accounting Officer568.55kN/A1983
Mr. James Paul Kastenmayer J.D., Ph.D.Consultant611.84kN/A1972
Joey PerroneVP of Fin. & Investor RelationsN/AN/AN/A
Dr. Kelly Boothe Ph.D.Sr. Director of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Cortney Caudill M.B.A.Chief Product OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Corporate governance

Aeglea BioTherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.